CRISPR Therapeutics AG $CRSP Shares Sold by Advisors Asset Management Inc.

Advisors Asset Management Inc. trimmed its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 10.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,885 shares of the company’s stock after selling 839 shares during the period. Advisors Asset Management Inc.’s holdings in CRISPR Therapeutics were worth $234,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. ARK Investment Management LLC increased its position in shares of CRISPR Therapeutics by 13.3% in the first quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company’s stock valued at $345,929,000 after buying an additional 1,192,336 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of CRISPR Therapeutics in the first quarter valued at approximately $416,000. Cambridge Investment Research Advisors Inc. increased its position in shares of CRISPR Therapeutics by 14.3% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 39,189 shares of the company’s stock valued at $1,334,000 after buying an additional 4,914 shares in the last quarter. Green Alpha Advisors LLC increased its position in shares of CRISPR Therapeutics by 132.9% in the first quarter. Green Alpha Advisors LLC now owns 57,361 shares of the company’s stock valued at $1,952,000 after buying an additional 32,732 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of CRISPR Therapeutics by 1.9% in the first quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock valued at $60,223,000 after buying an additional 33,711 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Simeon George acquired 989,812 shares of CRISPR Therapeutics stock in a transaction that occurred on Wednesday, July 16th. The shares were purchased at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. This represents a 133.69% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

CRSP has been the subject of a number of recent analyst reports. Chardan Capital restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Royal Bank Of Canada boosted their price objective on CRISPR Therapeutics from $38.00 to $42.00 and gave the company a “sector perform” rating in a research report on Tuesday, August 5th. Needham & Company LLC reissued a “buy” rating and set a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Wall Street Zen raised CRISPR Therapeutics to a “sell” rating in a research note on Friday, May 16th. Finally, Bank of America lowered their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, CRISPR Therapeutics presently has an average rating of “Hold” and an average price target of $71.60.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $55.89 on Friday. The business’s 50 day moving average price is $56.65 and its 200-day moving average price is $45.64. The firm has a market capitalization of $5.08 billion, a PE ratio of -10.29 and a beta of 1.81. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $6.44 million. During the same quarter last year, the business posted ($1.49) earnings per share. The firm’s revenue was up 72.5% compared to the same quarter last year. As a group, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.